Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma.

Daniel P Regan Lyndah ChowSunetra DasLaurel HainesEric PalmerJade N KuriharaJonathan W CoyAlissa MathiasDouglas H ThammDaniel L GustafsonSteven W Dow

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Losartan inhibits the CCL2-CCR2 axis, and in combination with toceranib, exerts significant biological activity in dogs with metastatic osteosarcoma, supporting evaluation of this drug combination in patients with pediatric osteosarcoma.

Keyphrases

squamous cell carcinoma
small cell lung cancer
dendritic cells
endothelial cells
emergency department
young adults
immune response
drug induced
electronic health record
childhood cancer